Literature DB >> 24945013

Cabazitaxel in castration resistant prostate cancer with brain metastases: 3 case reports.

Sabino De Placido1, Pasquale Rescigno1, Piera Federico1, Carlo Buonerba1, Davide Bosso1, Livio Puglia1, Michela Izzo1, Tania Policastro1, Giuseppe Di Lorenzo1.   

Abstract

Prostate cancer is the most common non-cutaneous malignancy for men. The skeleton is the most common metastatic site but, following an improvement in survival, metastases in uncommon sites are being found more frequently in clinical practice, especially brain metastases. Despite the new drugs now available for metastatic castration resistant prostate cancer, no clinical evidence exists about their effectiveness on brain metastases. We describe the clinical history of 3 patients treated with cabazitaxel plus whole brain radiotherapy. These case reports demonstrate that cabazitaxel is highly active and well tolerated in brain metastases.

Entities:  

Keywords:  Brain metastases; Cabazitaxel; Prostate cancer

Year:  2014        PMID： 24945013      PMCID： PMC4061315          DOI： 10.12998/wjcc.v2.i6.228

Source DB:  PubMed          Journal:  World J Clin Cases        ISSN： 2307-8960            Impact factor:   1.337


  12 in total

1.  Frequency of brain metastases from prostate cancer: an 18-year single-institution experience.

Authors:  Orazio Caffo; Antonello Veccia; Gianni Fellin; Salvatore Mussari; Lucianna Russo; Luigi Tomio; Enzo Galligioni
Journal:  J Neurooncol       Date:  2012-10-25       Impact factor: 4.130

2.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

Authors:  Johann Sebastian de Bono; Stephane Oudard; Mustafa Ozguroglu; Steinbjørn Hansen; Jean-Pascal Machiels; Ivo Kocak; Gwenaëlle Gravis; Istvan Bodrogi; Mary J Mackenzie; Liji Shen; Martin Roessner; Sunil Gupta; A Oliver Sartor
Journal:  Lancet       Date:  2010-10-02       Impact factor: 79.321

3.  Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats.

Authors:  Salvatore Cisternino; Fanchon Bourasset; Yves Archimbaud; Dorothée Sémiond; Gérard Sanderink; Jean-Michel Scherrmann
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

4.  Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer.

Authors:  Carlo Buonerba; Gregory R Pond; Guru Sonpavde; Piera Federico; Pasquale Rescigno; Livio Puglia; Davide Bosso; Antonella Virtuoso; Tania Policastro; Michela Izzo; Luca Vaccaro; Matteo Ferro; Michele Aieta; Sisto Perdonà; Giovannella Palmieri; Sabino De Placido; Giuseppe Di Lorenzo
Journal:  Future Oncol       Date:  2013-06       Impact factor: 3.404

5.  Peg-filgrastim and cabazitaxel in prostate cancer patients.

Authors:  Giuseppe Di Lorenzo; Carmine DʼAniello; Carlo Buonerba; Piera Federico; Pasquale Rescigno; Livio Puglia; Matteo Ferro; Davide Bosso; Carla Cavaliere; Giovannella Palmieri; Guru Sonpavde; Sabino De Placido
Journal:  Anticancer Drugs       Date:  2013-01       Impact factor: 2.248

6.  Cancer statistics, 2013.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2013-01-17       Impact factor: 508.702

7.  Brain metastasis from prostate carcinoma: The M. D. Anderson Cancer Center experience.

Authors:  Ivo W Tremont-Lukats; George Bobustuc; George K Lagos; Konstantinos Lolas; Athanassios P Kyritsis; Vinay K Puduvalli
Journal:  Cancer       Date:  2003-07-15       Impact factor: 6.860

8.  Distribution of metastatic sites in patients with prostate cancer: A population-based analysis.

Authors:  Giorgio Gandaglia; Firas Abdollah; Jonas Schiffmann; Vincent Trudeau; Shahrokh F Shariat; Simon P Kim; Paul Perrotte; Francesco Montorsi; Alberto Briganti; Quoc-Dien Trinh; Pierre I Karakiewicz; Maxine Sun
Journal:  Prostate       Date:  2013-10-16       Impact factor: 4.104

9.  Stereotactic radiosurgical treatment of parenchymal brain metastases from prostate adenocarcinoma.

Authors:  Se-Hyuk Kim; Samuel T Chao; Steven A Toms; Michael A Vogelbaum; Gene H Barnett; John H Suh; Robert J Weil
Journal:  Surg Neurol       Date:  2008-02-08

10.  Use of palliative radiotherapy in brain and bone metastases (VARA II study).

Authors:  Jose Expósito; Javier Jaén; Enrique Alonso; Isabel Tovar
Journal:  Radiat Oncol       Date:  2012-08-03       Impact factor: 3.481
View more
  4 in total

Review 1.  The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer.

Authors:  Martina Pagliuca; Carlo Buonerba; Karim Fizazi; Giuseppe Di Lorenzo
Journal:  Drugs       Date:  2019-03       Impact factor: 9.546

Review 2.  Radiotherapy for cranial and brain metastases from prostate cancer: a systematic review.

Authors:  Timothy L Sita; Katarina G Petras; Q Eileen Wafford; Mark A Berendsen; Tim J Kruser
Journal:  J Neurooncol       Date:  2017-05-25       Impact factor: 4.130

3.  Cranial Radiotherapy for Prostate Cancer Patients With Brain Metastases Inaccessible to Stereotactic Radiotherapy.

Authors:  Christina Schröder; Paul Windisch; Jamie Lütscher; Daniel R Zwahlen; Robert Förster
Journal:  In Vivo       Date:  2022 Jul-Aug       Impact factor: 2.406

4.  Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer.

Authors:  Giuseppe Di Lorenzo; Sergio Bracarda; Donatello Gasparro; Angela Gernone; Caterina Messina; Vittorina Zagonel; Livio Puglia; Davide Bosso; Davide Dondi; Guru Sonpavde; Giuseppe Lucarelli; Sabino De Placido; Carlo Buonerba
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.817
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.